Answers are grounded in this paper and cite their sources.
Introduction Pancreatic ductal adenocarcinoma (PDAC) remains a major global health challenge. While multidetector CT (MDCT) is the standard imaging modality for staging, the additional value of PET-CT in potentially resectable disease remains uncertain. Methods We conducted a six-year retrospective study of patients who underwent PET-CT for suspected PDAC. Demographics, cross-sectional imaging findings, PET-CT results, multidisciplinary team (MDT) decisions, operative outcomes, and histology were analysed. Rates of surgery with curative intent and time intervals between imaging and intervention were recorded. Results Among 161 patients, 110 were considered operable with curative intent, while 51 were deemed unsuitable for surgery. Of the operable group, 20 demonstrated extra-pancreatic PET-avid lesions and 90 did not. In patients without extra-pancreatic uptake, 68 underwent surgical exploration; 48 achieved successful resection and 20 were found to have unresectable disease. In 9 patients, suspected metastases on prior imaging were not confirmed on PET-CT. Among the 20 patients with extra-pancreatic lesions, PET-CT identified unequivocal metastases in 4, precluding surgery. The remaining 16 underwent exploration following MDT review; 9 were resectable and 7 were unresectable. Overall, PET-CT altered management in 8% of cases. The median interval between MDCT and PET-CT was 27 days, and between MDT discussion and PET/CT was 12.5 days. Conclusion PET-CT influences management in a minority of patients with potentially resectable PDAC, However, routine use may not be justified. Prospective studies are required to define clear selection criteria, and emerging artificial intelligence–based risk stratification tools may support more targeted and efficient utilisation in future practice
No takes yet. Share an insight, caveat, or question.
Saoudi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: